Cargando…

Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial

BACKGROUND: A highly efficacious vaccine is needed for malaria control and eradication. Immunization with Plasmodium falciparum NF54 parasites under chemoprophylaxis (chemoprophylaxis and sporozoite (CPS)-immunization) induces the most efficient long-lasting protection against a homologous parasite....

Descripción completa

Detalles Bibliográficos
Autores principales: Walk, Jona, Reuling, Isaie J., Behet, Marije C., Meerstein-Kessel, Lisette, Graumans, Wouter, van Gemert, Geert-Jan, Siebelink-Stoter, Rianne, van de Vegte-Bolmer, Marga, Janssen, Thorsten, Teelen, Karina, de Wilt, Johannes H. W., de Mast, Quirijn, van der Ven, André J., Diez Benavente, Ernest, Campino, Susana, Clark, Taane G., Huynen, Martijn A., Hermsen, Cornelus C., Bijker, Else M., Scholzen, Anja, Sauerwein, Robert W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598044/
https://www.ncbi.nlm.nih.gov/pubmed/28903777
http://dx.doi.org/10.1186/s12916-017-0923-4
_version_ 1783263821363675136
author Walk, Jona
Reuling, Isaie J.
Behet, Marije C.
Meerstein-Kessel, Lisette
Graumans, Wouter
van Gemert, Geert-Jan
Siebelink-Stoter, Rianne
van de Vegte-Bolmer, Marga
Janssen, Thorsten
Teelen, Karina
de Wilt, Johannes H. W.
de Mast, Quirijn
van der Ven, André J.
Diez Benavente, Ernest
Campino, Susana
Clark, Taane G.
Huynen, Martijn A.
Hermsen, Cornelus C.
Bijker, Else M.
Scholzen, Anja
Sauerwein, Robert W.
author_facet Walk, Jona
Reuling, Isaie J.
Behet, Marije C.
Meerstein-Kessel, Lisette
Graumans, Wouter
van Gemert, Geert-Jan
Siebelink-Stoter, Rianne
van de Vegte-Bolmer, Marga
Janssen, Thorsten
Teelen, Karina
de Wilt, Johannes H. W.
de Mast, Quirijn
van der Ven, André J.
Diez Benavente, Ernest
Campino, Susana
Clark, Taane G.
Huynen, Martijn A.
Hermsen, Cornelus C.
Bijker, Else M.
Scholzen, Anja
Sauerwein, Robert W.
author_sort Walk, Jona
collection PubMed
description BACKGROUND: A highly efficacious vaccine is needed for malaria control and eradication. Immunization with Plasmodium falciparum NF54 parasites under chemoprophylaxis (chemoprophylaxis and sporozoite (CPS)-immunization) induces the most efficient long-lasting protection against a homologous parasite. However, parasite genetic diversity is a major hurdle for protection against heterologous strains. METHODS: We conducted a double-blind, randomized controlled trial in 39 healthy participants of NF54-CPS immunization by bites of 45 NF54-infected (n = 24 volunteers) or uninfected mosquitoes (placebo; n = 15 volunteers) against a controlled human malaria infection with the homologous NF54 or the genetically distinct NF135.C10 and NF166.C8 clones. Cellular and humoral immune assays were performed as well as genetic characterization of the parasite clones. RESULTS: NF54-CPS immunization induced complete protection in 5/5 volunteers against NF54 challenge infection at 14 weeks post-immunization, but sterilely protected only 2/10 and 1/9 volunteers against NF135.C10 and NF166.C8 challenge infection, respectively. Post-immunization plasma showed a significantly lower capacity to block heterologous parasite development in primary human hepatocytes compared to NF54. Whole genome sequencing showed that NF135.C10 and NF166.C8 have amino acid changes in multiple antigens targeted by CPS-induced antibodies. Volunteers protected against heterologous challenge were among the stronger immune responders to in vitro parasite stimulation. CONCLUSIONS: Although highly protective against homologous parasites, NF54-CPS-induced immunity is less effective against heterologous parasite clones both in vivo and in vitro. Our data indicate that whole sporozoite-based vaccine approaches require more potent immune responses for heterologous protection. TRIAL REGISTRATION: This trial is registered in clinicaltrials.gov, under identifier NCT02098590. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12916-017-0923-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5598044
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55980442017-09-18 Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial Walk, Jona Reuling, Isaie J. Behet, Marije C. Meerstein-Kessel, Lisette Graumans, Wouter van Gemert, Geert-Jan Siebelink-Stoter, Rianne van de Vegte-Bolmer, Marga Janssen, Thorsten Teelen, Karina de Wilt, Johannes H. W. de Mast, Quirijn van der Ven, André J. Diez Benavente, Ernest Campino, Susana Clark, Taane G. Huynen, Martijn A. Hermsen, Cornelus C. Bijker, Else M. Scholzen, Anja Sauerwein, Robert W. BMC Med Research Article BACKGROUND: A highly efficacious vaccine is needed for malaria control and eradication. Immunization with Plasmodium falciparum NF54 parasites under chemoprophylaxis (chemoprophylaxis and sporozoite (CPS)-immunization) induces the most efficient long-lasting protection against a homologous parasite. However, parasite genetic diversity is a major hurdle for protection against heterologous strains. METHODS: We conducted a double-blind, randomized controlled trial in 39 healthy participants of NF54-CPS immunization by bites of 45 NF54-infected (n = 24 volunteers) or uninfected mosquitoes (placebo; n = 15 volunteers) against a controlled human malaria infection with the homologous NF54 or the genetically distinct NF135.C10 and NF166.C8 clones. Cellular and humoral immune assays were performed as well as genetic characterization of the parasite clones. RESULTS: NF54-CPS immunization induced complete protection in 5/5 volunteers against NF54 challenge infection at 14 weeks post-immunization, but sterilely protected only 2/10 and 1/9 volunteers against NF135.C10 and NF166.C8 challenge infection, respectively. Post-immunization plasma showed a significantly lower capacity to block heterologous parasite development in primary human hepatocytes compared to NF54. Whole genome sequencing showed that NF135.C10 and NF166.C8 have amino acid changes in multiple antigens targeted by CPS-induced antibodies. Volunteers protected against heterologous challenge were among the stronger immune responders to in vitro parasite stimulation. CONCLUSIONS: Although highly protective against homologous parasites, NF54-CPS-induced immunity is less effective against heterologous parasite clones both in vivo and in vitro. Our data indicate that whole sporozoite-based vaccine approaches require more potent immune responses for heterologous protection. TRIAL REGISTRATION: This trial is registered in clinicaltrials.gov, under identifier NCT02098590. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12916-017-0923-4) contains supplementary material, which is available to authorized users. BioMed Central 2017-09-13 /pmc/articles/PMC5598044/ /pubmed/28903777 http://dx.doi.org/10.1186/s12916-017-0923-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Walk, Jona
Reuling, Isaie J.
Behet, Marije C.
Meerstein-Kessel, Lisette
Graumans, Wouter
van Gemert, Geert-Jan
Siebelink-Stoter, Rianne
van de Vegte-Bolmer, Marga
Janssen, Thorsten
Teelen, Karina
de Wilt, Johannes H. W.
de Mast, Quirijn
van der Ven, André J.
Diez Benavente, Ernest
Campino, Susana
Clark, Taane G.
Huynen, Martijn A.
Hermsen, Cornelus C.
Bijker, Else M.
Scholzen, Anja
Sauerwein, Robert W.
Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial
title Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial
title_full Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial
title_fullStr Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial
title_full_unstemmed Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial
title_short Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial
title_sort modest heterologous protection after plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598044/
https://www.ncbi.nlm.nih.gov/pubmed/28903777
http://dx.doi.org/10.1186/s12916-017-0923-4
work_keys_str_mv AT walkjona modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial
AT reulingisaiej modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial
AT behetmarijec modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial
AT meersteinkessellisette modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial
AT graumanswouter modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial
AT vangemertgeertjan modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial
AT siebelinkstoterrianne modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial
AT vandevegtebolmermarga modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial
AT janssenthorsten modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial
AT teelenkarina modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial
AT dewiltjohanneshw modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial
AT demastquirijn modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial
AT vandervenandrej modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial
AT diezbenaventeernest modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial
AT campinosusana modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial
AT clarktaaneg modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial
AT huynenmartijna modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial
AT hermsencornelusc modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial
AT bijkerelsem modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial
AT scholzenanja modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial
AT sauerweinrobertw modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial